Cargando…
Umeclidinium/Vilanterol Compared with Fluticasone Propionate/Salmeterol, Budesonide/Formoterol, and Tiotropium as Initial Maintenance Therapy in Patients with COPD Who Have High Costs and Comorbidities
BACKGROUND: Comorbidities in patients with chronic obstructive pulmonary disease (COPD) are associated with increased medical costs and risk of exacerbations. This study compared COPD-related medical costs and exacerbations in high-cost, high-comorbidity patients with COPD receiving initial maintena...
Autores principales: | Kalhan, Ravi, Slade, David, Ray, Riju, Moretz, Chad, Germain, Guillaume, Laliberté, François, Shen, Qin, Duh, Mei Sheng, MacKnight, Sean Dale, Hahn, Beth |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8075186/ https://www.ncbi.nlm.nih.gov/pubmed/33911860 http://dx.doi.org/10.2147/COPD.S298032 |
Ejemplares similares
-
Hospital Admission and Readmission Among US Patients Receiving Umeclidinium/Vilanterol or Tiotropium as Initial Maintenance Therapy for Chronic Obstructive Pulmonary Disease
por: Slade, David, et al.
Publicado: (2021) -
Symptom Burden and GOLD Classification in Medicare Advantage Patients with COPD Initiating Umeclidinium/Vilanterol or Fluticasone Propionate/Salmeterol Therapy
por: Moretz, Chad, et al.
Publicado: (2020) -
Umeclidinium/vilanterol versus fluticasone propionate/salmeterol in COPD: a randomised trial
por: Singh, Dave, et al.
Publicado: (2015) -
Real-world effectiveness of umeclidinium/vilanterol versus fluticasone propionate/salmeterol as initial maintenance therapy for chronic obstructive pulmonary disease (COPD): a retrospective cohort study
por: Moretz, Chad, et al.
Publicado: (2019) -
Time-to-first exacerbation, adherence, and medical costs among US patients receiving umeclidinium/vilanterol or tiotropium as initial maintenance therapy for chronic obstructive pulmonary disease: a retrospective cohort study
por: Slade, David, et al.
Publicado: (2021)